First-void urine testing for high-risk human papillomavirus: A within-cohort comparison of three preanalytical approaches
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, cilt.117, sa.1, 2027 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 117 Sayı: 1
- Basım Tarihi: 2027
- Doi Numarası: 10.1016/j.diagmicrobio.2026.117712
- Dergi Adı: DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, Environment Index, MEDLINE, Academic Search Ultimate (EBSCO)
- Erciyes Üniversitesi Adresli: Evet
Özet
Objectives: To compare three preanalytical approaches for first-void urine (FVU)-based high-risk human papillomavirus (hrHPV) DNA detection against paired cervical swab (CS) specimens.
Methods: This cross-sectional observational study included 69 participants with a previous positive hrHPV screening result and paired CS and FVU specimens. From each FVU specimen, three urine preparations were generated: unpreserved urine, EDTA-treated urine for DNA stabilization, urine buffered with urine conservation medium (UCM; Novosanis, Wijnegem, Belgium). All specimens were analyzed using the QIAscreen HPV PCR Test (Qiagen, Hilden, Germany). Agreement with paired CS specimens, genotype-specific agreement, paired CS cycle threshold (Ct) values, and participant-reported perceptions of urine sampling were assessed.
Results: Overall agreement between urine and CS specimens was moderate across all three approaches, with Cohen's kappa values of 0.566 for unpreserved urine, 0.538 for EDTA-treated urine, and 0.581 for UCM-buffered urine. Paired CS Ct values were lower in participants with hrHPV DNA-positive urine specimens than in those with hrHPV DNA-negative urine specimens, consistent with greater urinary detectability at higher cervical hrHPV DNA levels. Genotype-specific agreement was stronger for HPV16 and HPV18 than for pooled non-16/18 hrHPV. Participant-reported data suggested good acceptability of urine sampling.
Conclusions: The three approaches showed broadly similar results to one another, while agreement with paired CS specimens was moderate across all approaches. These findings support further evaluation of urine-based hrHPV testing as a non-invasive sampling option that could help expand access to testing, particularly in lowincome and other resource-limited settings.